Loading clinical trials...

Use of Cefiderocol in the Management of Gram-Negative Infections | Clinical Trials | Clareo Health

COMPLETEDNCT05789199

Use of Cefiderocol in the Management of Gram-Negative Infections

The aim of this study is to describe the use of cefiderocol in the management of Gram-negative infections (GNIs) in participants treated through the Early Access Program (EAP) in Spain.

Lead sponsor: Shionogi•55 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

COMPLETED

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326 · Adenovirus, Anesthesia, and more

COMPLETEDPhase 4

Extended-infusion of Piperacillin-Tazobactam Versus Intermittent Infusion

NCT04895657 · Gram-Negative Infections

COMPLETEDPhase 1

MED Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Volunteers

NCT02707107 · Serious Gram-negative Infections

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 26, 2023Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment314

Start dateJul 2022

Last updatedJun 26, 2023

Condition

Gram-Negative Infection

Locations shown

Complejo Hospitalario Universitario A Coruña

A Coruña

Complejo Hospitalario Universitario de Albacete

Albacete

Hospital General Universitario de Alicante Doctor Balmis

Alicante

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 26, 2023Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions